Clinical Presentation and Treatment Outcomes of a Rare Hematologic Malignancy, Solitary Plasmacytoma: Single Center Experience
Beyhan Ceylaner Bıçakçı
S.B.Ü. Kartal Dr. Lütfi Kirdar City Hospital, Radiation Oncology Clinic, Istanbul, Turkey.
Fatih Demircioğlu *
S.B.Ü. Kartal Dr. Lütfi Kirdar City Hospital, Radiation Oncology Clinic, Istanbul, Turkey.
*Author to whom correspondence should be addressed.
Abstract
Aim: Solitary plasmacytoma(SP) is a rare hematological malignancy. In our study, we aimed to present the clinical presentation of this disease and the effects of radiotherapy on local control and survival as a single center experience.
Methodology: Case records of patients diagnosed with solitary plasmacytoma treated in our clinic between 2010-2022 were evaluated retrospectively. Radiotherapy was planned with 3D Conformal technique and IMRT techniques. Kaplan-Meier method was used for survival analysis and Cox univariate regression analysis was used for comparison of other data.
Results: Thirty-five of 44 patients whose files were screened met the inclusion criteria. Of these, 26 (74.3%) were solitary bone plasmacytoma (SBP) and 9 (25.7%) were extramedullary plasmacytoma (EMP). The thoracic vertebrae were the most common sites of SBP, while EMP most frequently occurred in the upper respiratory tract. The most common symptoms were pain and spinal compression. Median follow-up was 46.9 months. Multiple myeloma developed in 12 patients (34.3%) and secondary malignancy developed in three patients (8.6%) during follow-up. 1, 3 and 5-year survival rates were 94%, 80% and 76% respectively; median progression-free survival was 34.4 months.
Conclusion: We think that this study, in which we shared the data of a single center in the rare disease group, contributes to the literature in terms of detecting prognostic factors and managing the treatment process more accurately. Our results can be supported by multicenter studies that will include a larger number of patients.
Keywords: Plasmacytoma, radiotherapy, treatment outcomes, presentation
How to Cite
Downloads
References
Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Scientific World Journal. 2012;2012:895765.
Xuxing Shen, Shu Liu, Chao Wu, Jing Wang, Jianyong Li, Lijuan Chen. Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population-based study. Cancer Medicine; 2020.
DOI: 10.1002/cam4.3533
Sharpley FA, Neffa P, Panitsas F, Kothari J, Subesinghe M, Cutter D, et al. Long term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era. PLOS ONE . 2019; 14(7):e0219857.
Available:https://doi.org/10.1371/journal.pone.0219857
Terpos E, Kleber M, Engelhardt M, Zweegman S, GayF, Kastritis E, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254-66
Caers J, Paiva B, Zamagni E, Leleu X, Blade J, Kristinsson SY, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma:updated recommendations from a European Expert Panel. J Haematology & Oncology. 2018, 11:10
Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol. 1993;11:1311-5
Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruziello F,et al.18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluationof patients with multiple myeloma. J Nuclear Medicine:official publication, Society of Nuclear Medicine. 2008;49(2):195-200. Epub2008/01/18.
Available:https://doi.org/10.2967/jnumed.107.045641 PMID:18199607.
Agbuduwe C,Yang H,Gaglani J, Ajithkumar T.Clinical presentation and outcomes of solitary plasmacytoma in a tertiary hospital in the UK. Clinical Medicine. 2020;20 (5):e191-5.
DOİ: 10.7861/clinmed.2019-0488
de Waal EGM, Leene M,Veeger N, et al.progression of solitary plasmacytoma to multiple myeloma. A population based registry of the northern Netherlands. Br J Haematol 2016;175:661-7.
Thumallapally N, Meshref A, Mousa M,Terjanian T. Solitary plasmacytoma: population based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer 2017;17(13):2-11.
DOİ: 10.1186/s12885-016-3015-5
Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. Oncology(Williston Park).2000;14(1):101-8. 11; dicussion 11-2,15.
Li QW, Niu SQ, Wang HY, Wen G, Li YY, Xia YF, et al. Radiotherapy alone is associated with improved outcomes over surgery in the management of solitary plasmacytoma. Asian Pac J Cancer Prev. 2015;16(9): 3741-5.
Cox JD, Stetz J, & Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). International Journal of Radiation Oncology*Biology*Physics. 1995; 31(5): 1341–6.
Hyuna Sung PhD,Jacques Ferlay MSc, ME,Rebecca L. Siegel MPH,Mathieu Laversanne MSc,Isabelle Soerjomataram MD, MSc, PhD,Ahmedin Jemal DMV, PhD,Freddie Bray BSc, MSc, PhD. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49.
Available:https://doi.org/10.3322/caac.21660
El-Fattah MA, Aboelmagd M, Elhamouly M. Clinical risk factors of Plasmacytoma mortality: A US population-based study. British Journal of Haematology. 2017;179(1):161–2.
Epub 2016/06/14. 10.1111/bjh.14189 .
Finsinger P, Grammatico S, Chisini M, Piciocchi A, Foa R, Petrucci MT. Clinical features and prognostic factors in solitary plasmacytoma. British Journal of Haematology. 2016;172(4):554–60. Epub 2015/12/20. 10.1111/bjh.13870
Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. American journal of hematology. 2012;87(7):647–51. Epub 2012/05/03. 10.1002/ajh.23201
Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):210–7.
Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117(18):4701–5.
Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC, et al. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. American Journal of Hematology. 2014;89(8):803–8.
Epub 2014/04/24. 10.1002/ajh.23745.
Graça M. Dores,Ola Landgren, Katherine A. McGlynn, Rochelle E. Curtis, Martha S. Linet, Susan S. Devesa. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: Incidence and survival in the United States, 1992−2004. Br J Haematol. 2009; 144(1): 86–94.
DOİ: 10.1111/j.1365-2141.2008.07421.x
Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. International journal of radiation oncology, biology, physics. 2001;50(1):113–20.
Epub 2001/04/24. 10.1016/s0360-3016(00)01572-8
Basavaiah SH, Lobo FD, Philipose CS, Suresh PK, Sreeram S, Kini H et al. Clinicopathological spectrum of solitary Plasmacytoma: a single center experience from coastal India. BMC Cancer 2019;19:801.
Available: https://doi.org/10.1186/s12885-019-5976-7
Soutar R, Lucraft H, Jackson G, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124 (6):717–26.
Sasaki R, Yasuda K, Abe E, et al. Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(2):626–34.
bataille R, sany J. Solitary myeloma: Clinical and prognostic features of areview of 114 cases. Cancer. 1981;48:845-51
frassica da,frassica FJ,Schray MF,Sim FH, Kyle RA. Solitary plasmacytoma of bone:Mayo cliniv experience. Int J Radiat Oncol Biol Phys. 1989;16:43-8.
Mendenhall CM, Thar TL, Million RR. Solitary plasmacytoma of bone and soft tissue. International Journal of Radiation Oncology, Biology, Physics. 1980;6(11): 1497–501.
Epub 1980/11/01. 10.1016/0360-3016(80)90006-1
Aviles A, Huerta-Guzman J, Delgado S, et al. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol. 1996;14(3):111–7.
Eısenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version1.1) Eur J Cancer. 2009;45:228-47.